Volume 5, Number 41
Monday, October 17, 2005



In this issue: (click heading to view article)
Variations in Treatment Among Adult-Onset Open-Angle Glaucoma Patients
Microbial Hand Contamination in a Tertiary Care Ophthalmic Outpatient Practice
Differences in Keratoconus as a Function of Gender: The CLEK Study Group
Systemic Hypertension and Glaucoma: Mechanisms in Common and Co-Occurrence
Perfluorocarbon Liquid as a Short-Term Post-Op Tamponade for Giant Retinal Tears
Briefly











Variations in Treatment Among Adult-Onset Open-Angle Glaucoma Patients

The Wilmer Eye Institute at Johns Hopkins Medical Institutions conducted a retrospective cohort study of people enrolled in a large managed-care organization to determine the predictors of treatment for glaucoma and suspect glaucoma in a nationally representative sample of diagnosed persons.

The study included 35,754 four diagnosed suspects, 5,265 diagnosed glaucoma patients, and 2,633 people coded as having cupping of the optic disc. Researchers used linked pharmacy and patient care information to examine the predictors of initiating glaucoma treatment in this cohort of persons insured by a single managed care organization. Predictors entered into logistic regression models included diagnostic group (suspect vs. diagnosed), age group, gender, region of the country, provider type at the initial visit (optometrist or ophthalmologist), diagnosis index date divided into two periods (1995 to 1998 and 1999 to 2001) and health plan enrollment duration after the initial diagnosis. Main outcome measures were occurrence of and factors associated with treatment for glaucoma (argon laser trabeculoplasty [ALT], surgery or topical ocular hypotensives).

A logistic regression model adjusting for glaucoma status, age, region, clinician seen at initial visit and index date found that women were 24 percent less likely to undergo treatment (topical ocular hypotensives, ALT or surgery) than men, and that younger individuals were far less likely to be treated than older ones. Furthermore, treatment varied by region of the country. The authors believe that understanding the sources of these variations will help in determining how to arrive at better management strategies for individuals with glaucoma and suspect glaucoma.

SOURCE: Friedman DS, Nordstrom B, Mozaffari E, Quigley HA. Variations in treatment among adult-onset open-angle glaucoma patients. Ophthalmol. 2005 Sep;112(9):1494-9.
Table of Contents










Microbial Hand Contamination in a Tertiary Care Ophthalmic Outpatient Practice

Investigators at the University of Hong Kong (China) measured the extent of microbial hand contamination among ophthalmologists during routine clinic practice and examined its association with hand cleansing practices and beliefs, glove use and patient load.

The study was a single-masked analysis of resident and transient flora of ophthalmologists before and after patient examination and after hand washing by agar imprints of the dominant hand. Researchers used standardized questionnaires to collect information concerning subjects" hand cleansing practices and patient load.

Of the 108 cultures, 107 (99.1 percent) were culture positive, yielding 15 separate organisms. Gram-negative bacilli were the most common transient flora, followed by Gram-positive cocci and fungi. Thirty-five (97.2 percent) ophthalmologists were culture positive for at least one resident and eight (22.2 percent) ophthalmologists were culture positive for at least one transient organism, before patient contact. Regression models showed alcohol-based hand rub use, transient and resident floral load before patient contact and patient load collectively accounted for 58.7 percent of the variance in resident floral load after patient contact. Use of alcohol-based hand rubs was associated with a mean resident floral reduction of 324.4 CFUs and 31.6 CFUs after patient contact and hand washing, respectively. Hand washing with chlorhexidine was a significant predictor for transient floral load after hand washing.

The authors found that the extent of contamination with pathogenic organisms after contact with eye outpatients, who have traditionally been perceived as relatively "clean," was of concern. Previously identified risk factors for hand contamination in inpatient settings, such as patient load, only explained a small proportion of variance in microbial load in the ophthalmic outpatient setting.

SOURCE: Lam RF, Hui M, Leung DY, et al. Extent and predictors of microbial hand contamination in a tertiary care ophthalmic outpatient practice. Invest Ophthalmol Vis Sci. 2005 Oct;46(10):3578-83.
Table of Contents











Differences in Keratoconus as a Function of Gender: The CLEK Study Group

Investigators in the Collaborative Longitudinal Evaluation of Keratoconus (CLEK) Study at Ohio State University’s College of Optometry found gender differences in patient history, vision, and ocular symptoms in keratoconus patients.

The observational, longitudinal study included 1,209 subjects at 16 clinics. For eye-specific categorical variables, investigators counted the number of eyes per subject with the characteristic. For eye-specific continuous variables, they calculated the mean of both eyes. They created multivariate linear (for continuous outcomes) and logistic (for categorical outcomes) regression models for each baseline characteristic with statistically significant differences between men and women. Age, race, education and corneal curvature were covariates.

Results showed that the women were older, more likely to report a family history of keratoconus, more likely to be nonwhite and less likely to complete college than men in the study. Vogt’s striae and monocular and binocular high-contrast entrance acuity were the only visual characteristics that varied between men and women in the multivariate model. Women were more likely than men to report ocular symptoms of dryness and complaints based upon a composite score of ocular symptoms. Women reported more hours per day of near work and were less likely to report the ability to wear contact lenses for enough hours to permit reading at home in the evening. Women also reported more visits to their eye care practitioner during the previous 12 months. NEI-VFQ results revealed differences in self-reported difficulty with distance activities and driving.

SOURCE: Fink BA, Wagner H, Steger-May K, et al. (Collaborative Longitudinal Evaluation of Keratoconus [CLEK] study group). Differences in keratoconus as a function of gender. Am J Ophthalmol. 2005;140(3):459.e1-459.e12.
Table of Contents











Systemic Hypertension and Glaucoma: Mechanisms in Common and Co-Occurrence

This British study aimed to determine whether systemic hypertension and glaucoma might coexist more often than expected, with possible implications for treatment.

In a case-control study using general practitioner database of 27,080 patients with glaucoma matched with controls for age and sex, hypertension was significantly more common in the patients with glaucoma (odds ratio [OR] 1.29, 95 percent confidence intervals [CI] 1.23 to 1.36) than in controls. Treatment by oral beta blockade appeared to protect from risk, but oral calcium channel antagonists or angiotensin converting enzyme (ACE) inhibitors did not. Oral corticosteroid treatment was associated with enhanced risk.

The authors of the study believe that common pathogenetic mechanisms in ciliary and renal tubular epithelia may explain the coincidence of glaucoma and systemic hypertension. The choice of cardiovascular treatment could substantially influence glaucoma incidence, with beta blockade protecting and ACE-inhibitors or calcium channel blockers not affecting underlying risk.

SOURCE: Langman MJ, Lancashire RJ, Cheng KK, Stewart PM. Systemic hypertension and glaucoma: mechanisms in common and co-occurrence. Br J Ophthalmol. 2005;89(8):960-3.
Table of Contents











Perfluorocarbon Liquid as a Short-Term Post-Op Tamponade for Giant Retinal Tears

Perfluorocarbon liquid appears safe and effective to use as a short-term postoperative tamponade in managing retinal detachment from giant retinal tears, according to a retrospective consecutive case series study by Australia’s Sydney Eye Hospital.

The study included 62 eyes of 61 patients with retinal detachment from giant retinal tears who underwent vitrectomy using perfluorocarbon liquid as a short-term postoperative internal tamponade. The perfluorocarbon liquid was removed 5 to 14 days (mean 7.5 days) later and replaced by gas or silicone oil. Scleral buckling was performed in some cases with proliferative vitreoretinopathy. The surgeon removed the crystalline lens if there was interference with the surgical view or if it was subluxated. Investigators assessed the success rate of retinal reattachment, visual outcome and postoperative complications.

Follow-up time ranged from 8 to 69 months (mean 24.5 months). All retinas were attached intraoperatively. Fourteen eyes (22.6 percent) developed re-detachment; additional operations were performed in 13 eyes. At final visit, 58 eyes (93.5 percent) had retinas that remained attached with visual acuity 20/40 or better in 27 eyes (46.5 percent). The visual acuity improved in 34 eyes (54.8 percent) with 28 eyes (45.2 percent) improving at least two Snellen lines. It was unchanged in 20 eyes (32.3 percent) and was worse in eight eyes (12.9 percent). Three patients developed glaucoma that was controlled medically. No retained perfluorocarbon liquid was found in any eyes.

SOURCE: Sirimaharaj M, Balachandran C, Chan WC, et al. Vitrectomy with short term postoperative tamponade using perfluorocarbon liquid for giant retinal tears. Br J Ophthalmol. 2005;89(9):1176-9.
Table of Contents









BRIEFLY
  • AMO TO DISCONTINUE NON-CORE CATARACT AND EYECARE PRODUCTS. Advanced Medical Optics (AMO) is accelerating its previously announced repositioning program and plans on discontinuing "all non-core cataract and eyecare products and eliminating non-core assets related to these products" by the end of 2005. The company will increase its investment in the growth of its refractive product line, and it is actively pursuing entry into the artificial tear market. AMO says that while it’s pleased with the overall performance of its laser-correction business and growth trends remain favorable for its cataract and refractive-implant brands, its eyecare business has been challenged by the shrinking hydrogen-peroxide market.
  • BAUSCH & LOMB ANNOUNCES MEDICARE REIMBURSEMENT TERMS FOR RETISERT. The Centers for Medicare & Medicaid Services has designated the single-indication orphan drug Retisert (fluocinolone acetonide intravitreal implant), 0.59 mg, eligible for Medicare pass-through payment under the Hospital Outpatient Prospective Payment System (OPPS). The designation became effective October 1, 2005. The payment rate to hospitals billing for Retisert using HCPCS code C9225 is set at $19,345, as reported in the October 2005 update of OPPS Addendum A on the CMS website, www.cms.hhs.gov/providers/hopps. The payment methodology is based upon 106 percent of wholesale acquisition cost. Coding and payment amounts for non-Medicare procedures vary by insurer. Retisert was approved as a single-indication orphan drug by the FDA last April for treating chronic noninfectious uveitis affecting the posterior segment of the eye; Bausch & Lomb launched Retisert in the United States in June.
  • TREATMENT WITH MACUGEN MAY PROVIDE BETTER RESULTS FOR EARLY STAGE NEOVASCULAR AMD. Eyetech Pharmaceuticals, Inc. and Pfizer, Inc. announced that exploratory analyses of the VEGF Inhibition Study in Ocular Neovascularization (VISION) study suggest that treatment with Macugen (pegaptanib sodium injection) 0.3 mg may provide better results in patients with early stage neovascular age-related macular degeneration (AMD) compared to the overall VISION study population. The findings were published in the October issue of Retina and will be presented at the American Academy of Ophthalmology meeting on October 18, 2005. The subgroup analyses suggest that for patients with early disease receiving Macugen 0.3 mg, responder rates (loss of less than 15 letters of visual acuity) were higher than previously seen in the overall Macugen 0.3 mg group in the VISION study (76 percent and 80 percent in the two early disease groups, compared with 70 percent in the overall 0.3 mg Macugen group). In addition, 12 percent and 20 percent of Macugen-treated patients in the two early disease subgroups gained three or more lines of vision, compared with 4 percent and 0 percent, respectively, in the usual care group (compared with 6 percent Macugen vs. 2 percent usual care in the overall VISION study). Since the VISION study was not designed to evaluate these subgroup responses, future studies are needed to prospectively investigate the impact of treatment with Macugen for early stage neovascular AMD.

Table of Contents




 Check Yearly. See Clearly. Open Your Eyes To the Opportunities.
It"s only been up and running a few short weeks. Yet, it"s already clear that the Check Yearly. See Clearly.(SM) marketing campaign is opening consumers" eyes to the benefits of regular eye exams. Call the Vision Council of America at 800-424-8422 today or visit checkyearly.com for your free promotional materials.